|View printer-friendly version|
Bellicum Announces Late-Breaking Poster Presentation on TCR Product Candidate with Activation Switch at the American Association for Cancer Research (AACR) 2016 Annual Meeting
The presentation, titled “Go-TCR: Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells, Increasing Anti-Tumor Efficacy” will highlight preclinical data demonstrating that its novel “go” switch can augment activation and expansion of TCR-engineered T cells while sensitizing tumors to T cells via cytokine-induced MHC class I upregulation.
The poster will be available in the Events & Presentations section of the Bellicum website at the time of the presentation.
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Bellicum may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue," “designed,”
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things: our
research and development activities relating to iMC, CAR T, TCRs or
Go-TCRs; the effectiveness of iMC, CAR T, TCRs or Go-TCRs, their
possible range of application and potential curative effects and safety
in the treatment of diseases; and the potential applications and
effectiveness of our product candidates, including as compared to other
treatment options and competitive therapies. Various factors may cause
differences between Bellicum’s expectations and actual results as
discussed in greater detail under the heading “Risk Factors” in
Bellicum’s filings with the